Kelleher Craig

10% Owner Millstreet Capital sells 100,000 DBD shares for $8.5M at $84.80; retains 4.10M shares

Millstreet Capital Management LLC, a 10% owner, executed an open-market sale of 100,000 shares (100.0K shares) at $84.80 on 2026-06-26, reducing its position from 4.20M shares to 4.10M shares—a -2.4% decrease. The sale occurred against a backdrop of strong near-term stock performance: DBD has gained 4.8% over the past 30 days and 9.5% over 90 days, trading at $85.02 (within 4.5% of its 52-week high of $89.05). Notably, this sale is part of a recent rapid-trading pattern at DBD: Millstreet executed five separate sells between June 8–15, 2026, all within a compressed one-week window, with outcome measurements not yet available for timing evaluation. Across Millstreet's broader cross-ticker insider history, prior sells have been poorly timed: 15 prior sells showed an average 90-day return of +11.0%, meaning the stock rose after the insider sold, with a 14.29% well-timed rate—below a neutral threshold. The company's fundamentals show modest growth (revenue +1.5% YoY, latest quarterly revenue $891.8M) against a P/E of 27.25, leaving DBD trading at elevated valuation relative to fundamentals.

10% Owner Millstreet Capital sold 231,464 shares for $19.4M at DBD; 5 sells in 14 days, reducing stake to 4.20M shares

Millstreet Capital Management, holding 4.20M shares post-transaction, executed 2 separate sales on consecutive days (June 24–25, 2026) totaling 231,464 shares for $19,434,340.12 at blended average price $83.96. This -5.2% reduction follows a sequence of 5 prior sales at DBD within a 14-day window (June 8–15), establishing a clear pattern of systematic stake reduction in a compressed timeframe. The stock price has appreciated 8.9% over 30 days and 13.3% over 90 days from transaction date, and currently trades at $84.98, near the 52-week high of $89.05. Against Millstreet's cross-ticker track record of 15 prior sells with 14.29% well-timed rate (suggesting generally poor timing outcomes at the 90-day horizon, with average +11.0% 90-day return), the rapid succession of DBD sales warrants scrutiny of whether they represent confidence-driven reduction, liquidity needs, or portfolio rebalancing.

10% owner Millstreet Capital sells 161,440 DBD shares in two transactions for $13,260,296.33, reducing holdings by 3.5%

Millstreet Capital Management LLC, a 10% owner of Diebold Nixdorf, executed 2 separate sales totaling 161,440 shares for $13,260,296.33 at an average blended price of $82.14, reducing its post-transaction stake to 4,435,896 shares from 4,597,336 shares. The stock currently trades at $82.16, essentially flat to the sale prices, while the company's P/E of 26.33 and modest 1.5% annual revenue growth suggest a mature valuation. Historically, this insider's prior trades at DBD show mixed timing: 3 of 5 recent sells resulted in negative 90-day returns (well-timed), while 2 generated positive 90-day returns, indicating the insider has occasionally sold before declines but without consistent precision. The cross-ticker track record shows a 40.00% well-timed rate with an average 90-day return of +6.8% after sells, meaning this insider's sells have more often been followed by stock appreciation across other holdings.

Millstreet Capital (10% owner) sold 18,768 shares at avg $82.08 for $1.5M; retains 4.60M shares post-transaction.

Millstreet Capital Management LLC, a 10% owner, executed two separate sales totaling 18,768 shares for $1,540,490.60 on 2026-06-10 and 2026-06-11 at a blended average price of $82.08. The transaction represents a -0.4% reduction in holdings, leaving the filer with 4,597,336 shares. The sales occurred when DBD was trading near recent highs—the current price of $81.68 is -8.3% from the 52-week high of $89.05—and the stock has gained +13.4% over the prior 30 days and +12.7% over the prior 90 days. At the same ticker, Millstreet's prior five trades show mixed timing outcomes: three of five prior sales were well-timed at the 90-day mark, though recent April 2026 sales showed negative 30-day and 90-day returns of -17.8% and -3.7%, respectively. With a P/E of 26.18 and modest annual revenue growth of +1.5%, the fundamental backdrop is unexceptional relative to the valuation.

10% owner Millstreet Capital sold 88,334 shares of DBD at $82.99 on 2026-06-08 for $7,330,988.83; stock now $80.79.

Millstreet Capital Management LLC, a 10% owner, sold 88,334 shares at $82.99, reducing holdings from 4,704,438 to 4,616,104 shares. The sale price is -9.3% from the 52-week high of $89.05. At this same ticker, Millstreet's prior 5 trades at DBD show mixed post-sale returns: 3 of 5 prior sells achieved negative 90-day returns, indicating the insider has been somewhat successful at timing exits downward. However, the cross-ticker track record shows an average 90-day return of +6.8% after sells, and a well-timed rate of 40.00%, suggesting inconsistent execution across different holdings. DBD's fundamentals show Revenue of $891,800,000.00 with modest Net income of $5,000,000.00 and Annual revenue growth of only +1.5%, paired with a P/E of 25.89 on a $2,797,627,789.68 market cap.

10% owner Millstreet Capital sells 112,305 shares over 2 days for $9,554,387.85; stock at 52-week high.

Millstreet Capital Management LLC executed two separate sales totaling 112,305 shares for $9,554,387.85 at prices of $85.43 and $84.77 on April 15–16, 2026, reducing holdings by 2.3% to 4,704,438 shares. The sales occurred as DBD trades at $88.77, matching its 52-week high after a +24.2% 30-day rally and +27.0% 90-day gain. Reviewing Millstreet's prior DBD sales, 0 of 4 measurable trades were well-timed at the 90-day mark (all showed positive 90-day returns, meaning stock rose after each sale). At the cross-ticker level, the insider's prior sells averaged +0.2% 30-day return and +11.0% 90-day return with a 14.29% well-timed rate. The sale size and timing relative to recent momentum merit monitoring, but the persistent pattern of post-sale price appreciation at this ticker suggests discretionary positioning rather than a material adverse-information signal.

10% owner Millstreet Capital sold 399,929 shares of DBD at $82.42 on 2026-04-08 for $32,960,468.48, reducing stake to 4,816,743 shares

Millstreet Capital Management LLC, holding approximately 10% of Diebold Nixdorf, executed a substantial open-market sale of 399,929 shares (399.9K shares) at $82.42 on 2026-04-08, yielding $32,960,468.48 ($33.0M) and reducing the stake by -7.7% to 4,816,743 shares (4.82M shares). The sale occurred near the stock's 52-week high of $84.78 and on the heels of strong momentum: +12.7% over 30 days and +25.8% over 90 days. Examining the insider's prior trading pattern at DBD—5 previous sales at this ticker—reveals a consistent pattern: 0 of 4 measurable prior sells proved well-timed at the 90-day horizon (all produced positive 90-day returns ranging from +7.1% to +12.8%), meaning the stock rallied after each prior sale. This current transaction, executed after sustained stock appreciation and near the 52-week peak, may follow the same pattern of selling into strength rather than selling before declines. The company's modest fundamentals (P/E of 18.43, +1.5% annual revenue growth, $41.1M net income on $945.2M revenue) offer limited fundamental catalyst for outsized upside, though present no immediate red flag.

10% owner Millstreet Capital sells 500,000 DBD shares at $68.00 for $34.0M; stock at 52-week high territory after +21.1% in 90 days.

Millstreet Capital Management LLC, holding 5.22M shares (5.22M shares post-sale), sold 500,000 shares at $68.00 on 2026-01-15 for $34,000,000.00, reducing its stake by 8.7%. The sale occurs near the 52-week high ($70.27), with the stock at $68.61 currently—down 2.4% from its peak but up 21.1% over the past 90 days. Across his cross-ticker track record, this insider's 6 prior sells showed a 90-day well-timed rate of 25.00%, suggesting poor post-sale stock performance; however, at DBD specifically, only 1 of 3 prior 90-day measurable outcomes was well-timed (negative return), with the other two selling sessions followed by gains of +11.2% and +11.1%. Company fundamentals show revenue growth of +8.4% year-over-year and a P/E of 48.66, but the company was unprofitable on a full-year basis, presenting a mixed picture. The confluence of near-52-week-high pricing, strong recent momentum, and a concentrated sale warrants monitoring for further insider activity signals.

10% owner Millstreet Capital sold 251,726 shares of DBD for $15.9M; remains 5.72M shares, P/E 45.74 amid unprofitable full year.

Millstreet Capital Management LLC, a 10% owner of Diebold Nixdorf, executed 2 separate sales totaling 251,726 shares for $15,906,629.83 on 2025-11-05 and 2025-11-06 at a blended average price of $63.19, reducing holdings by 4.2% while retaining 5,716,672 shares. The stock has appreciated 12.2% over the past 30 days and trades at a P/E of 45.74 near its 52-week high of $65.60, though the company reported negative full-year net income despite 8.4% annual revenue growth. At the same ticker, Millstreet's prior 4 sales yielded 1 of 2 measurable 90-day outcomes as well-timed (a 50% success rate), whereas the most recent sales in September showed declines of 6.8% and 5.5% in the 30-day window, followed by an earlier May 2024 sale that fell 9.9% in 30 days. This liquidation at elevated valuation multiples and near a 52-week high follows a pattern of elevated recent selling activity at the same ticker and occurs as the stock's fundamental underpinnings—unprofitability despite revenue growth and a richly valued P/E—merit scrutiny.

10% Owner Millstreet Capital sold 38,963 shares of DBD at $60.08; stock now $57.54, down 8.8% in 30 days

Millstreet Capital Management LLC, a 10% owner, sold 38,963 shares on 2025-09-18 at $60.08, reducing its DBD stake from 6,007,361 shares to 5,968,398 shares. The sale represents a minor portfolio adjustment of -0.6% of pre-transaction holdings. The transaction occurred at a price $2.54 above the current market price of $57.54, and the stock has declined 8.8% over the past 30 days. In Millstreet's same-ticker DBD history, 1 of 2 prior measurable sells were well-timed at the 90-day mark (the 2024-05-23 sell posted a -7.6% 90-day return, while the 2024-03-20 sale returned +17.9%). The company reported a recent quarterly revenue of $915,200,000, annual revenue growth of +8.4%, but remains unprofitable with net income of $12,200,000 in the latest quarter against a full-year loss. The mixed timing record at this specific ticker, combined with the modest scale of the sale and the company's precarious profitability, suggests this warrant further monitoring of whether additional liquidation follows.